Firefly Bio

Firefly Bio is a biotechnology company specializing in Degrader Antibody Conjugates (DACs), a novel approach to cancer treatment. Their proprietary platform combines the strengths of Antibody Drug Conjugates (ADCs) and protein degraders, resulting in highly specific delivery of payloads to target tissue. Firefly's DACs overcome limitations of traditional ADCs and protein degraders, allowing for precise targeting of intracellular biological targets with minimal collateral damage. This innovative technology has shown promising results in preclinical studies, demonstrating significant reductions in tumor volume at very low doses.

Firefly is a young company founded in 2024, but they have assembled a team of experienced executives with deep expertise in biotech creation, ADC development, and degrader chemistry. Backed by a leading syndicate including founding investor Versant Ventures, MPM BioImpact, Decheng Capital and Eli Lilly & Company, Firefly is well positioned to become a leader in the discovery and development of clinically meaningful DACs in oncology and immunology.

Firefly Bio offers a flexible work environment with benefits such as flexible time off and family leave. This allows employees to balance their personal and professional lives and work in a way that suits them best.

Firefly Bio offers a comprehensive benefits package for employees, encompassing health insurance with medical, prescription, dental, and vision coverage, as well as voluntary options. Long-term benefits include 401k matching, an equity program, life insurance, AD&D insurance, and disability insurance. The company promotes work/life balance with flexible time off, family leave, and company holidays. Additionally, employees enjoy company perks such as hosted lunches, onsite gym access, a public transport shuttle, holiday events, and happy hours.

Firefly Bio aims to revolutionize the treatment of cancer by developing a new class of therapeutics called Degrader Antibody Conjugates (DACs). Their innovative platform combines the strengths of antibody drug conjugates (ADCs) and protein degraders, creating highly specific delivery of payloads to target tissues with minimal collateral damage. By leveraging their proprietary Firelink linker technology, Firefly's DACs can precisely target a range of intracellular biological targets that were previously inaccessible due to therapeutic index issues.

Firefly Bio cultivates a fast-paced and collaborative work environment that values innovation, integrity, respect, and positive energy. They encourage diverse perspectives and actively seek individuals who are passionate about scientific and technological advancements, fostering a culture of ambition and shared purpose.

Firefly Bio emphasizes a culture of diverse minds and bright sparks, actively seeking individuals from various backgrounds to join their team. They are dedicated to exploring complex and exciting challenges, implying a commitment to inclusive problem-solving and valuing different perspectives. Their commitment to diversity is reflected in their team composition and hiring practices, showcasing a conscious effort to create an inclusive and welcoming environment.